Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Intrinsic Value
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. [ Read More ]
The intrinsic value of one
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
stock under the Base Case scenario is
43.79
CNY.
Compared to the current market price of 68.26 CNY,
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
is
Overvalued by 36%.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's market capitalization is 86.4B CNY.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock price is 68.26 CNY.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock (43.79 CNY) is 36% less than its price (68.26 CNY).
Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock (43.15 CNY) is 37% less than its price (68.26 CNY). Open DCF Valuation
Beijing Wantai Biological Pharmacy Enterprise Co Ltd stock (44.43 CNY) is 35% less than its price (68.26 CNY). Open Relative Valuation
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has upside potential of 4% compared to the average analyst price target.
Open Wall St Estimates
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 10%.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Revenue has dropped by 51% over the past 12 months.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 40% to 10%.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 36% to 14%.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has positive Free Cash Flow for the last twelve months.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has positive Net Income for the last twelve months.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Revenue has been growing by an exceptional 33% per year for the last 3 years.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has positive Operating Income for the last twelve months.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has positive Gross Profit for the last twelve months.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has very high three-year average ROE (Return on Equity): 44%. The company is very efficient at transforming stockholders' equity into net income.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has very high three-year average ROIC (Return on Invested Capital): 47%. The company is very efficient at using invested capital to generate operating income.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's short-term assets (10B CNY) exceed its short-term liabilties (3B CNY).
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.02.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's long-term assets (16B CNY) exceed its long-term liabilties (3B CNY).
Beijing Wantai Biological Pharmacy Enterprise Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (6B CNY) than debt (301m CNY).
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Altman Z-Score is very high and is equal to 20.43.
Valuation Backtest
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Run backtest to discover the historical profit from buying and selling
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Balance Sheet Decomposition
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
| Current Assets | 10.3B |
| Cash & Short-Term Investments | 6.2B |
| Receivables | 3.1B |
| Other Current Assets | 980m |
| Non-Current Assets | 5.4B |
| Long-Term Investments | 1.4B |
| PP&E | 2.9B |
| Intangibles | 642.7m |
| Other Non-Current Assets | 455.6m |
| Current Liabilities | 2.7B |
| Accounts Payable | 299.9m |
| Accrued Liabilities | 268.5m |
| Short-Term Debt | 173.1m |
| Other Current Liabilities | 1.9B |
| Non-Current Liabilities | 344.4m |
| Long-Term Debt | 127.7m |
| Other Non-Current Liabilities | 216.7m |
Earnings Waterfall
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
|
Revenue
|
5.5B
CNY
|
|
Cost of Revenue
|
-992.7m
CNY
|
|
Gross Profit
|
4.5B
CNY
|
|
Operating Expenses
|
-3.1B
CNY
|
|
Operating Income
|
1.4B
CNY
|
|
Other Expenses
|
-158.6m
CNY
|
|
Net Income
|
1.2B
CNY
|
Free Cash Flow Analysis
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Profitability Score
Profitability Due Diligence
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
According to Wall Street analysts, the average 1-year price target for
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
is 70.82 CNY
with a low forecast of 51.82 CNY and a high forecast of 103.95 CNY.
Shareholder Return
Price
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
| Average Annual Return | 558.87% |
| Standard Deviation of Annual Returns | 948.69% |
| Max Drawdown | -80% |
| Market Capitalization | 86.4B CNY |
| Shares Outstanding | 1 268 206 999 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. The company is headquartered in Beijing, Beijing and currently employs 3,103 full-time employees. The company went IPO on 2020-04-29. The firm produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The firm is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.
Contact
IPO
Employees
Officers
The intrinsic value of one
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
stock under the Base Case scenario is
43.79
CNY.
Compared to the current market price of 68.26 CNY,
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
is
Overvalued by 36%.
You don't have any saved screeners yet
